Back to ALDXView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMAPending
Xiidra
Treatment of moderate to severe dry eye disease in adults for whom prior artificial tears has not been sufficient
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3
Proliferative Vitreoretinopathy
Reproxalap Ophthalmic Solution (0.25%) QIDPhase 3
Dry Eye
Reproxalap Ophthalmic Solution (0.5%)Phase 3
Allergic Conjunctivitis
ADX-102 1% Topical Dermal Cream (reproxalap)Phase 3
Sjogren-Larsson Syndrome
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BIDPhase 3
Dry Eye
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts